An open-label Phase I/IIa study to evaluate the safety and efficacy of CCS1477 as monotherapy and in combination in patients with advanced haematological malignancies.
Datos básicos
Documentos
- No hay documentos
Grupos
Financiadores - Promotores
CELLCENTRIC LTD
Cita
An open-label Phase I/IIa study to evaluate the safety and efficacy of CCS1477 as monotherapy and in combination in patients with advanced haematological malignancies. (CCS1477-02). CELLCENTRIC LTD. 2025IP:JAVIER DE LA RUBIA COMOS.
Portal de investigación